Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
Dr. Shereef Elsamany
14 : 00 – 14 : 10
Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer.
Dr. Esam Murshid
14 : 10 – 14 : 20
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).
Dr Metab Alfohaidi
14 : 20 – 14 : 30
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC)
Dr. Abokhair Algahmi
14 : 30 – 14 : 40
EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting (San Antonio 2022) .
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
Dr. Mervat Mahrous
17 : 35 – 17 : 45
KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
Dr. Ahmed A. Refae
17 : 45 – 17 : 55
The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).
Dr. Abdullah Al Twigri
17 : 55 – 18 : 05
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
Dr. Shadi AlKhayyat
18 : 05 – 18 : 15
SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).
Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk
Dr. Nedal Bukhari
09 : 45 – 09 : 55
Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.
DR. Amin ElTigani
09 : 55 – 10 : 05
Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial
Dr. Faisal Azam
10 : 05 – 10 : 15
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426
Dr. Fahad Bin Shamsa
10 : 15 – 10 : 25
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.
Dr. Mubarak Almansour
10 : 25 – 10 : 40
Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design
Dr. Yasser Bahader
10 : 40 – 10 : 50
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
Dr. Rula AlMofti
11 : 05 – 11 : 30
Abstract Discussion (Practice changing Abstracts)
DR. Guillermo de Velasco 🇪🇸
11 : 30 – 11 : 45
Q&A and Panel Discussion
11 : 45 – 12 : 15
Satellite symposium (Janssen) Topic: Updates on the management of mHSPC
ChairPerson : Dr. Essam Murshid Speaker : Dr. Aisha Alharbi
12 : 15 – 12 : 45
Satellite symposium (BMS) Topic:Treating Gastric cancer today. Clinical practice in KSA
ChairPerson : Dr. Ashwaq Alolayan Speaker : Dr. Kanan Alshammari
12 : 45 – 13 : 30
Prayer & LUNCH Break
GI cancer Session
Dr. Hoda Mokhtar
Dr. Mohamed Alfayaz
Dr. Hazem Alotabi
Dr. Waleed Alselwi
Dr. Ahmed Mostafa
Dr. Ghanim Almotiri
13 : 30 – 13 : 40
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
Dr. Fahad Almokbal
13 : 40 – 13 : 50
Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.
Dr. Ahmed Alshehri
13 : 50 – 14 : 00
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial
Dr. Kanan Alshamari
14 : 00 – 14 : 10
Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.
Dr. Safwan Bakhsh
14 : 10 – 14 : 20
Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
Dr. Mohamed Algarni
14 : 20 – 14 : 30
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial
14 : 30 – 14 : 40
NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC).
Dr. Ashwaq Alolayan
14 : 40 – 15 : 10
Abstract Discussion (What is Practice changing one)